New antibody drug tested in fight against aggressive blood cancers
NCT ID NCT05428969
Summary
This early-phase study is testing a new antibody drug called bexmarilimab in combination with standard cancer therapies. It aims to find a safe dose and see if the combination helps adults with advanced forms of blood cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The research focuses on patients whose disease is high-risk or has not responded well to prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Helsinki University Hospital
Helsinki, 00029, Finland
-
Kuopio University Hospital
Kuopio, 70210, Finland
-
Oulu University Hospital
Oulu, 90029, Finland
-
Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom
-
Tampere University Hospital
Tampere, 33520, Finland
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.